

**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

**SECTION 1: Identification of the substance/mixture and of the company/undertaking****1.1 Product identifier**

Trade name : Oxfendazole / Oxytoclozanide Formulation

**1.2 Relevant identified uses of the substance or mixture and uses advised against**

Use of the Sub-  
stance/Mixture : Veterinary medicine

Recommended restrictions  
on use : Not applicable

**1.3 Details of the supplier of the safety data sheet**

Company : MSD  
20 Spartan Road  
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

**1.4 Emergency telephone number**

+1-908-423-6000

---



**SECTION 2: Hazards identification****2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Reproductive toxicity, Category 1B	H360FD: May damage fertility. May damage the unborn child.
Specific target organ toxicity - single exposure, Category 2	H371: May cause damage to organs.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

**2.2 Label elements****Labelling (REGULATION (EC) No 1272/2008)**

## Oxfendazole / Oxytoclozanide Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 7942486-00008      Date of last issue: 30.09.2023  
 Date of first issue: 19.03.2021

- Hazard pictograms :  
- Signal word : Danger
- Hazard statements : H360FD May damage fertility. May damage the unborn child.  
 H371 May cause damage to organs.  
 H373 May cause damage to organs through prolonged or repeated exposure.  
 H410 Very toxic to aquatic life with long lasting effects.
- Precautionary statements : **Prevention:**  
 P201 Obtain special instructions before use.  
 P260 Do not breathe dust.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- Response:**  
 P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
 P391 Collect spillage.

Hazardous components which must be listed on the label:

oxytoclozanide  
 oxfendazole

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

## 3.2 Mixtures

## Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
oxytoclozanide	2277-92-1 218-904-0	Repr. 2; H361d STOT SE 2; H371 (Central nervous system) STOT RE 2; H373 (Brain, Liver)	>= 30 - < 50

## Oxfendazole / Oxytoclozanide Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 7942486-00008      Date of last issue: 30.09.2023  
 Date of first issue: 19.03.2021

		Aquatic Acute 1; H400 Aquatic Chronic 1; H410 <hr/> M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	
oxfendazole	53716-50-0 258-714-5	Repr. 1B; H360FD STOT RE 2; H373 (Liver, Testis) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 <hr/> M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 1	>= 20 - < 25

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.  
 Never give anything by mouth to an unconscious person.

**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

**4.2 Most important symptoms and effects, both acute and delayed**

Risks : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

May damage fertility. May damage the unborn child.  
May cause damage to organs.  
May cause damage to organs through prolonged or repeated exposure.

**4.3 Indication of any immediate medical attention and special treatment needed**

Treatment : Treat symptomatically and supportively.

---

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Chlorine compounds  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides  
Oxides of phosphorus

**5.3 Advice for firefighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**7.2 Conditions for safe storage, including any incompatibilities**

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal

**8.2 Exposure controls****Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

## Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	:	powder
Colour	:	white to off-white, light cream, cream
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable

**Oxfendazole / Oxcyclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

Relative density	:	No data available
Density	:	0,88 g/cm <sup>3</sup>
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Molecular weight	:	No data available
------------------	---	-------------------

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

**10.4 Conditions to avoid**

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

**10.5 Incompatible materials**

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of : Inhalation



## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

exposure

Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

|| Not classified based on available information.

**Components:****oxyclozanide:**

|| Acute oral toxicity : LD50 (Rat): 3.519 mg/kg  
Target Organs: Central nervous system

|| Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

**oxfendazole:**

|| Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg  
  
LD50 (Dog): 1.600 mg/kg  
  
LD50 (sheep): 250 mg/kg

**Skin corrosion/irritation**

|| Not classified based on available information.

**Components:****oxyclozanide:**

|| Remarks : Not classified due to lack of data.

**oxfendazole:**

|| Species : Rabbit  
|| Result : No skin irritation

**Serious eye damage/eye irritation**

|| Not classified based on available information.

**Components:****oxyclozanide:**

|| Remarks : Not classified due to lack of data.

**oxfendazole:**

|| Species : Rabbit  
|| Result : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

|| Not classified based on available information.

## Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

**Respiratory sensitisation**

|| Not classified based on available information.

**Components:****oxyclozanide:**

Exposure routes	:	Dermal
Remarks	:	Not classified due to lack of data.

**Germ cell mutagenicity**

|| Not classified based on available information.

**Components:****oxyclozanide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**oxfendazole:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive

**Carcinogenicity**

|| Not classified based on available information.

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

**Components:****oxyclozanide:**

Remarks : Not classified due to lack of data.

**oxfendazole:**

Species : Rat  
 Application Route : Oral  
 Exposure time : 1 Years  
 Symptoms : No adverse effects  
 Target Organs : Liver

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Symptoms : No adverse effects  
 Target Organs : Liver

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****oxyclozanide:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat, male and female  
 Application Route: Oral  
 General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight  
 Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development  
 Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Oral  
 General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight  
 Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development  
 Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Oral  
 Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight  
 Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Oral  
 General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight  
 Result: No fetotoxicity, No teratogenic effects, No effects on

## Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

	fertility
Effects on foetal development	: Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
	Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
	Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity, Skeletal malformations
Reproductive toxicity - Assessment	: Suspected of damaging the unborn child.

**oxfendazole:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0,9 mg/kg body weight Target Organs: Liver Result: No effects on fertility
	Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects
	Test Type: Embryo-foetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

<div style="border-left: 3px double black; height: 100px; margin-left: 10px;"></div>	<p>Result: positive, Embryo-foetal toxicity</p> <p>Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities</p> <p>Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0,625 mg/kg body weight</p>
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**
 May cause damage to organs.
**Components:****oxyclozanide:**

	Exposure routes	: Oral
	Target Organs	: Central nervous system
	Assessment	: May cause damage to organs.

**STOT - repeated exposure**
 May cause damage to organs through prolonged or repeated exposure.
**Components:****oxyclozanide:**

	Target Organs	: Brain, Liver
	Assessment	: May cause damage to organs through prolonged or repeated exposure.

**oxfendazole:**

	Exposure routes	: Oral
	Target Organs	: Liver, Testis
	Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****oxyclozanide:**

	Species	: Rat
	NOAEL	: 9 mg/kg
	LOAEL	: 44,5 mg/kg
	Application Route	: Oral
	Exposure time	: 3 Months

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

Target Organs	: Brain, Liver, spleen, Adrenal gland
Symptoms	: Liver effects
Species	: Dog
NOAEL	: 5 mg/kg
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver
Symptoms	: blood effects, alteration in liver enzymes

**oxfendazole:**

Species	: Rat
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis
Species	: Rat
NOAEL	: 3,8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis
Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver
Species	: Mouse
NOAEL	: 37,5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver
Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported
Species	: Dog
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland
Species	: Dog
NOAEL	: 13,5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

**Aspiration toxicity**

|| Not classified based on available information.

**Components:****oxclozanide:**

|| Not applicable

**Experience with human exposure****Components:****oxclozanide:**

|| Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

**SECTION 12: Ecological information****12.1 Toxicity****Components:****oxclozanide:**

|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,69 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

|| M-Factor (Acute aquatic toxicity) : 1

|| M-Factor (Chronic aquatic toxicity) : 1

**oxfendazole:**

|| Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2,7 mg/l  
Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2,5 mg/l  
Exposure time: 96 h

|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,059 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

|| Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

|| M-Factor (Acute aquatic toxicity) : 10

## Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

icity)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0,023 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

## 12.2 Persistence and degradability

Components:**oxyclozanide:**

Stability in water : Hydrolysis: 50 %(156 d)  
Method: OECD Test Guideline 111

**oxfendazole:**

Stability in water : Hydrolysis: < 5 %(4 d)

## 12.3 Bioaccumulative potential

Components:**oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3,99  
pH: 7  
Method: OECD Test Guideline 107

**oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1,95

## 12.4 Mobility in soil

Components:**oxyclozanide:**

Distribution among environmental compartments : log Koc: 4,83  
Method: OECD Test Guideline 106

**oxfendazole:**

Distribution among environmental compartments : log Koc: 3,2

## 12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.



**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations.  
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information****14.1 UN number**

ADN : UN 3077  
ADR : UN 3077  
RID : UN 3077  
IMDG : UN 3077  
IATA : UN 3077

**14.2 UN proper shipping name**

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxytoclozanide)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxytoclozanide)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxytoclozanide)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxytoclozanide)

IATA : Environmentally hazardous substance, solid, n.o.s.  
(oxfendazole, oxytoclozanide)

**14.3 Transport hazard class(es)**

## Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

**14.4 Packing group****ADN**

Packing group	: III
Classification Code	: M7
Hazard Identification Number	: 90
Labels	: 9

**ADR**

Packing group	: III
Classification Code	: M7
Hazard Identification Number	: 90
Labels	: 9
Tunnel restriction code	: (-)

**RID**

Packing group	: III
Classification Code	: M7
Hazard Identification Number	: 90
Labels	: 9

**IMDG**

Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F

**IATA (Cargo)**

Packing instruction (cargo aircraft)	: 956
Packing instruction (LQ)	: Y956
Packing group	: III
Labels	: Miscellaneous

**IATA (Passenger)**

Packing instruction (passenger aircraft)	: 956
Packing instruction (LQ)	: Y956
Packing group	: III
Labels	: Miscellaneous

**14.5 Environmental hazards****ADN**

Environmentally hazardous	: yes
---------------------------	-------

**ADR**

Environmentally hazardous	: yes
---------------------------	-------

**RID**

Environmentally hazardous	: yes
---------------------------	-------

**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

**IMDG**

Marine pollutant : yes

**IATA (Passenger)**

Environmentally hazardous : yes

**IATA (Cargo)**

Environmentally hazardous : yes

**14.6 Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H360FD : May damage fertility. May damage the unborn child.

H361d : Suspected of damaging the unborn child.

H371 : May cause damage to organs if swallowed.

H373 : May cause damage to organs through prolonged or repeated exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

**Full text of other abbreviations**

Aquatic Acute : Short-term (acute) aquatic hazard

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

## Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Repr. 1B	H360FD
STOT SE 2	H371
STOT RE 2	H373
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

**Oxfendazole / Oxytoclozanide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	14.04.2025	7942486-00008	Date of first issue: 19.03.2021

---

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN